North America Insulin Delivery Devices Market Size (2024 - 2029)

The North America Insulin Delivery Devices Market is projected to experience growth over the forecast period, driven by increased demand from diabetes patients, particularly those affected by COVID-19. The pandemic highlighted the vulnerability of individuals with diabetes, leading to a heightened need for insulin delivery devices as patients sought to manage their conditions more closely. This demand was supported by manufacturers' efforts to ensure consistent supply during the crisis. The market's expansion is further influenced by the complexities of diabetes management, which often requires frequent insulin adjustments to prevent complications, thereby increasing the reliance on these devices.

Market Size of North America Insulin Delivery Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
North America Insulin Delivery Devices Market Summary
Study Period 2019- 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 14.59 Million
Market Size (2029) USD 18.91 Million
CAGR (2024 - 2029) 5.06 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

North America Insulin Delivery Devices Market Analysis

The North America Insulin Delivery Devices Market size is estimated at USD 14.59 million in 2024, and is expected to reach USD 18.91 million by 2029, growing at a CAGR of 5.06% during the forecast period (2024-2029).

The COVID-19 pandemic has substantially impacted the North America Insulin Delivery Devices Market. Type-1 diabetes patients are impacted more during COVID-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin delivery devices.

In North America, till April 2022, the United States had the highest number of COVID cases with 82 million, the country also registered the highest death rate. According to the Diabetes Voice, close to 40,000 people who died were having diabetes. In the North American region diabetes patients were more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Insulin Delivery Devices Industry Segmentation

There are different ways to inject insulin into a patient's body using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The North America insulin delivery devices market is segmented into type (insulin pumps, insulin syringes, cartridges in reusable pens, disposable pens, and jet injectors) and geography (Canada, United States, rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Type
Insulin Pumps
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Cartridges in Reusable Pens
Disposable Pens
Jet Injectors
Geography
Canada
United States
Rest of North America
Need A Different Region Or Segment?
Customize Now

North America Insulin Delivery Devices Market Size Summary

The North American insulin delivery devices market is poised for significant growth over the forecast period, driven by the increasing prevalence of diabetes and the rising demand for effective management solutions. The market is characterized by a moderate level of consolidation, with major players such as Novo Nordisk, Sanofi, Eli Lilly and Company, and Medtronic leading the charge. The COVID-19 pandemic has underscored the importance of these devices, as individuals with diabetes faced heightened health risks, prompting a surge in demand for insulin delivery solutions. The market's expansion is further supported by advancements in technology, such as the integration of continuous glucose monitoring systems with automated insulin delivery systems, which enhance the ease and effectiveness of diabetes management.

In the United States and Canada, the diabetes epidemic continues to grow, with millions of individuals living with diabetes or prediabetes. This rising prevalence has spurred the development and adoption of insulin delivery devices, as patients seek minimally intrusive yet effective treatment options. The market is also influenced by regulatory support and healthcare policies that facilitate access to insulin and related therapies. As awareness of diabetes management increases and new products are introduced, the North American insulin delivery devices market is expected to experience robust growth, offering promising opportunities for both established and emerging players in the industry.

Explore More

North America Insulin Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Type

      1. 2.1.1 Insulin Pumps

        1. 2.1.1.1 Insulin Pump Device

        2. 2.1.1.2 Insulin Pump Reservoir

        3. 2.1.1.3 Infusion Set

      2. 2.1.2 Insulin Syringes

      3. 2.1.3 Cartridges in Reusable Pens

      4. 2.1.4 Disposable Pens

      5. 2.1.5 Jet Injectors

    2. 2.2 Geography

      1. 2.2.1 Canada

      2. 2.2.2 United States

      3. 2.2.3 Rest of North America

North America Insulin Delivery Devices Market Size FAQs

The North America Insulin Delivery Devices Market size is expected to reach USD 14.59 million in 2024 and grow at a CAGR of 5.06% to reach USD 18.91 million by 2029.

In 2024, the North America Insulin Delivery Devices Market size is expected to reach USD 14.59 million.

North America Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)